# Proviva Therapeutics

Source: https://onco.cc/companies/proviva-therapeutics/  
OnCo record `proviva-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Proviva Therapeutics is testing PTX-912, an engineered form of the immune signal IL-2 designed to switch on mainly inside tumours, in an early trial in the United States for people with advanced solid tumours.

## Summary

Proviva Therapeutics (博致生物) develops cytokine immunotherapies using what it calls a Crossover cytokine prodrug platform, designed to release activity in the tumour microenvironment and limit the systemic toxicity of cytokines. Its lead candidate, PTX-912, is described in its March 2024 Series A announcement as an immune-cell-targeted IL-2 prodrug fusion protein and in its December 2025 Series A+ announcement as a PD-1/IL-2 prodrug fusion protein. PTX-912 is in a first-in-human phase 1a/1b trial in locally advanced or metastatic solid tumours (NCT06190886), sponsored by Proviva Therapeutics, Inc., at US sites including City of Hope and the University of Miami. Financing: an $18 million Series A in March 2024 with Longpan Capital and others, and a Series A+ of over $30 million announced in December 2025, led by OrbiMed. The Chinese operating company is registered in the Shanghai Free Trade Zone and was established in August 2019; OrbiMed's portfolio page also says it was founded in 2019.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Proviva Therapeutics, Inc.; 博致生物; 博致生物科技（上海）有限公司
- HQ: Shanghai
- Type: biotech

## Notes

- The company website (provivatx.com) did not respond, so no website is given and company facts come from the registry, OrbiMed and Chinese financing reports.
- HQ is the registered address of the Shanghai operating company; the US entity's address was not found.
- Sources describe PTX-912 differently (IL-2 prodrug fusion protein; PD-1/IL-2 prodrug fusion protein), so no target is linked.
- NCT06190886 has no OnCo trial record.

## Sources

- PTX-912 phase 1 trial NCT06190886: https://clinicaltrials.gov/study/NCT06190886
- Series A report (PEdaily, March 2024): https://news.pedaily.cn/202403/530729.shtml
- Company registry data and Series A+ notice (PharnexCloud): https://www.pharnexcloud.com/trz/trz_ded7210b75b2b633ad7fd29246debfb2
- OrbiMed portfolio entry: https://www.orbimed.com/portfolio/

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/), [Immunocytokines (antibody-cytokine fusions)](https://onco.cc/technologies/immunocytokines/)
- drugs: [PTX-912](https://onco.cc/drugs/ptx-912/)
- companies: [OrbiMed](https://onco.cc/companies/orbimed/)
- trials: [A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06190886/)

---
JSON: https://onco.cc/api/v1/entities/proviva-therapeutics.json